Annual report pursuant to Section 13 and 15(d)

Intangible Assets and In-Process R&D

v3.10.0.1
Intangible Assets and In-Process R&D
12 Months Ended
Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets Disclosure [Text Block]
6. Intangible Assets and In-Process R&D
 
Intangible assets at December 31, 2018 consist of the rights to trade secrets and know-how related to the manufacturing of the EyeGate Ocular Bandage Gel (“OBG”). During the third quarter of 2018, the Company entered into an intellectual property license agreement with SentrX Animal Care, Inc. (“SentrX”) with respect to certain rights relating to the manufacturing of the EyeGate OBG product. The intangible assets were recorded at $250,000, representing the upfront payment paid to SentrX. Additionally, SentrX is eligible to receive milestone payments totaling up to $4.75 million, upon and subject to the achievement of certain specified development and commercial milestones. These future milestone payments to SentrX will increase the carrying value of the intangible assets. 
The Company’s intangible assets are amortized on a straight-line basis over the estimated useful lives. 
Additionally, in-process R&D at December 31, 2018 and 2017 consists of projects acquired from the acquisition of Jade that have not reached technological feasibility and which have no alternative future use. Once the R&D process is complete, the Company will amortize the R&D asset over its remaining useful life. 
The Company 
periodically evaluates these assets for impairment.
 
Intangible assets and in-process R&D at December 31, 2018 and 2017 consists of the following:
 
 
 
Estimated Useful
Life (Years)
 
2018
 
 
2017
 
Trade Secrets
 
10
 
$
250,000
 
 
$
-
 
Less: Accumulated Amortization
 
 
 
 
(6,250
)
 
 
-
 
Intangible Assets, Net
 
 
 
 
243,750
 
 
 
-
 
In-Process R&D
 
 
 
 
3,912,314
 
 
 
3,912,314
 
Total Intangible Assets and In-Process R&D, Net
 
 
 
$
4,156,064
 
 
$
3,912,314
 
 
Amortization expense on intangible assets was $6,250 and $0 for the years ended December 31, 2018 and 2017, respectively.